Cooper Companies (NASDAQ:COO) Issues Q4 2026 Earnings Guidance

Key Points

• Cooper Companies lowered expectations for profitability: Q4 2026 EPS guidance of $1.05–$1.09 trails the $1.20 consensus, while FY 2026 EPS guidance of $4.51–$4.55 is below the $4.63 analyst estimate. Revenue guidance is broadly in line with expectations.
• Shares fell 6.2% to $63.48 after the guidance update, trading well below their 50-day and 200-day moving averages.
• The company completed its strategic review and will retain CooperSurgical, while increasing its share-repurchase authorization from $2 billion to $3 billion. Analysts collectively rate the stock “Hold,” with an average price target of $81.64.

Cooper Companies (NASDAQ:COO - Get Free Report) issued an update on its fourth quarter 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 1.050-1.090 for the period, compared to the consensus earnings per share estimate of 1.200. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion. Cooper Companies also updated its FY 2026 guidance to 4.510-4.550 EPS.

Cooper Companies Trading Down 6.2%

COO traded down $4.21 during mid-day trading on Wednesday, hitting $63.48. The stock had a trading volume of 8,383,881 shares, compared to its average volume of 2,347,124. The stock's fifty day simple moving average is $72.59 and its 200-day simple moving average is $70.17. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.27 and a quick ratio of 0.78. The firm has a market capitalization of $12.38 billion, a price-to-earnings ratio of 53.80, a price-to-earnings-growth ratio of 1.82 and a beta of 0.82. Cooper Companies has a 1-year low of $58.89 and a 1-year high of $89.83.

Cooper Companies (NASDAQ:COO - Get Free Report) last announced its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $1.12 by $0.03. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, research analysts forecast that Cooper Companies will post 4.63 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

COO has been the subject of a number of research analyst reports. UBS Group assumed coverage on Cooper Companies in a research note on Tuesday, July 28th. They issued a "neutral" rating and a $75.00 target price for the company. BNP Paribas Exane decreased their price objective on Cooper Companies from $95.00 to $92.00 and set an "outperform" rating for the company in a research report on Monday, June 8th. JPMorgan Chase & Co. decreased their price objective on Cooper Companies from $80.00 to $71.00 and set a "neutral" rating for the company in a research report on Friday, June 5th. Weiss Ratings reissued a "sell (d)" rating on shares of Cooper Companies in a research note on Friday. Finally, Mizuho set a $85.00 price target on shares of Cooper Companies and gave the company an "outperform" rating in a research note on Thursday, June 4th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $81.64.

Key Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: CooperCompanies increased its share-repurchase authorization from $2 billion to $3 billion. The larger buyback could support earnings per share and signal that management views the stock as undervalued. The company also said its board remains open to other value-creation options. CooperCompanies Completes Strategic Review, Increases Share Repurchase Authorization
• Neutral Sentiment: CooperCompanies completed its strategic review and unanimously decided to retain CooperSurgical. While the decision removes uncertainty around the business, it also means the company will not receive a potential near-term cash infusion from a sale or separation. CooperCompanies Completes Strategic Review, Increases Share Repurchase Authorization
• Neutral Sentiment: The company released fiscal third-quarter 2026 results for the period ended July 31. The supplied announcement does not include the reported revenue or earnings figures, so the market’s reaction is likely being driven primarily by the forward guidance. CooperCompanies Announces Third Quarter 2026 Results
• Negative Sentiment: Fiscal 2026 adjusted EPS guidance of $4.51–$4.55 is below the consensus estimate of $4.63. Revenue guidance of $4.2–$4.3 billion is also below or only reaches the $4.3 billion consensus at the high end, suggesting weaker-than-expected growth or profitability.
• Negative Sentiment: Fourth-quarter 2026 EPS guidance of $1.05–$1.09 is well below the $1.20 consensus estimate. Although revenue guidance of approximately $1.1 billion is broadly in line with expectations, the earnings shortfall indicates pressure on margins, costs, or the business mix.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Cresset Asset Management LLC lifted its stake in Cooper Companies by 7.5% in the 3rd quarter. Cresset Asset Management LLC now owns 4,393 shares of the medical device company's stock valued at $301,000 after acquiring an additional 306 shares in the last quarter. Captrust Financial Advisors grew its stake in shares of Cooper Companies by 10.0% during the 2nd quarter. Captrust Financial Advisors now owns 3,500 shares of the medical device company's stock worth $249,000 after acquiring an additional 317 shares in the last quarter. Snowden Capital Advisors LLC raised its holdings in shares of Cooper Companies by 10.0% in the second quarter. Snowden Capital Advisors LLC now owns 4,088 shares of the medical device company's stock valued at $291,000 after purchasing an additional 373 shares during the last quarter. Public Employees Retirement System of Ohio raised its holdings in shares of Cooper Companies by 0.6% in the third quarter. Public Employees Retirement System of Ohio now owns 62,229 shares of the medical device company's stock valued at $4,266,000 after purchasing an additional 386 shares during the last quarter. Finally, Arkadios Wealth Advisors lifted its position in shares of Cooper Companies by 14.3% in the fourth quarter. Arkadios Wealth Advisors now owns 3,552 shares of the medical device company's stock worth $291,000 after purchasing an additional 444 shares in the last quarter. 24.39% of the stock is currently owned by institutional investors.

About Cooper Companies

Cooper Companies, Inc NASDAQ: COO is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women's health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.